International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis

Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years. Study hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original drug Rebif®.

Start Date12 Feb 2015

Sponsor / Collaborator

Biocad CJSC

100 Clinical Results associated with Interferon beta-1a biosimilar(Biocad Medical, Inc.)

100 Translational Medicine associated with Interferon beta-1a biosimilar(Biocad Medical, Inc.)

100 Patents (Medical) associated with Interferon beta-1a biosimilar(Biocad Medical, Inc.)

128

Literatures (Medical) associated with Interferon beta-1a biosimilar(Biocad Medical, Inc.)

01 Nov 2024·CNS Drugs

Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis

Review

Author: Nie, Tina ; Syed, Yahiya Y ; Syed, Yahiya Y.

Ozanimod (Zeposia^®), an orally administered sphingosine 1-phosphate (S1P) receptor modulator (S1PRM) that is selective for the S1P₁ and S1P₅ receptor subtypes, is approved in the USA for relapsing forms of multiple sclerosis (RMS). In pivotal phase III clinical trials in patients with RMS, ozanimod significantly reduced annualised relapse rates and the number of new or enlarging T2 lesions and gadolinium-enhancing lesions, and was associated with reduced brain volume loss, compared with interferon (IFN)-β1a. However, there were no significant differences in 3- and 6-month disability progression between the groups. Ozanimod was generally well tolerated, with the most common adverse reactions including upper respiratory tract infection and hepatic transaminase elevation. Efficacy and tolerability were sustained over more than 6 years with continued treatment. S1PRM-related adverse events seen with ozanimod are generally manageable with screening and/or monitoring. Notably, ozanimod does not require first-dose cardiac monitoring in the USA. In conclusion, ozanimod is a valuable once-daily oral disease-modifying therapy that extends the available treatment options for patients with RMS.

01 Apr 2024·Acta Neurologica Belgica

Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic

Article

Author: Danilović, Miloš ; Savić, Dejan ; Vojinović, Slobodan ; Todorović, Stefan ; Aleksić, Dejan

BACKGROUND/AIMDisease-modifying therapy (DMT) has led to added challenges in the management of people with multiple sclerosis (pwMS) during the COVID-19 era. It can reduce relapse in MS or slow down disease progression, but some DMTs can increased risk of infection. The aim of study was to evaluate risk and severity of COVID-19 in pwMS.METHODSThe examined group of pwMS were divided in group treated with IFN-β1a, group treated with ocrelizumab and untreated group. The examination included impact of age, gender, duration of MS, type of MS, vaccination status and Expanded Disability Status Scale (EDSS) on the risk and severity of COVID-19 infection. A diagnosis of COVID-19 in pwMS was confirmed by positive polymerase-chain-reaction (PCR) or antigen test.RESULTSOut of 207 pwMS, 82 patients were treated with ocrelizumab, 63 with IFN-β1a, while 62 patients were untreated pwMS. The average duration of the MS was longer in the group of patients treated with ocrelizumab than in the group treated with IFN-β1a (p < 0.05). EDSS was higher in the ocrelizumab group compared to the other two groups (p < 0.001). Untreated (more often unvaccinated) had the same COVID frequency as ocrelizumab-treated (more vaccinated, but higher EDSS). The multivariate logistic regression model indicated that administration of IFN-β1a reduces the risk of COVID-19 infection (p = 0.001, OR = 0.381, 95% CI 0.602-0.160). The use of both DMTs, driven mainly by the IFN-β1a effect, reduces the risk of moderate and severe COVID-19 (p < 0.05, OR = 0.105, 95% CI 0.011-0.968).CONCLUSIONThis study provides evidence that IFN-β1a can reduce the frequency of COVID-19 infection and that two DMTs, driven mainly by the IFN-β1a effect, do not increase the risk of moderate/severe COVID-19.

01 Jun 2023·Pharmacology research & perspectives

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.

Review

Author: Espérou, Hélène ; Tacconelli, Evelina ; Delmas, Christelle ; Costagliola, Dominique ; Paiva, José Artur ; Poissy, Julien ; Greil, Richard ; Staub, Thérèse ; Saillard, Juliette ; Ader, Florence ; Dumousseaux, Marina ; Burdet, Charles ; Mentre, France ; Diallo, Alpha ; Fougerou-Leurent, Claire ; Belhadi, Drifa ; Le Mestre, Soizic ; Peiffer-Smadja, Nathan ; Ferrane, Assia ; Yazdanpanah, Yazdan ; Andrejak, Claire ; Hites, Maya ; Mercier, Noémie ; DeChanet, Aline

The current COVID-19 pandemic was an exceptional health situation, including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different drug candidates were proposed. In this article, we present the challenges for an academic Safety Department to manage the global safety of a European trial during the pandemic. The National Institute for Health and Medical Research (Inserm) conducted a European multicenter, open-label, randomized, controlled trial involving three repurposed and one-in development drugs (lopinavir/ritonavir, IFN-β1a, hydroxychloroquine, and remdesivir) in adults hospitalized with COVID-19. From 25 March 2020 to 29 May 2020, the Inserm Safety Department had to manage 585 Serious Adverse Events (SAEs) initial notification and 396 follow-up reports. The Inserm Safety Department's staff was mobilized to manage these SAEs and to report Expedited safety reports to the competent authorities within the legal timeframes. More than 500 queries were sent to the investigators due to a lack of or incoherent information on SAE forms. At the same time, the investigators were overwhelmed by the management of patients suffering from COVID-19 infection. These particular conditions of missing data and lack of accurate description of adverse events made evaluation of the SAEs very difficult, particularly the assessment of the causal role of each investigational medicinal product. In parallel, working difficulties were accentuated by the national lockdown, frequent IT tool dysfunctions, delayed implementation of monitoring and the absence of automatic alerts for SAE form modification. Although COVID-19 is a confounding factor per se, the delay in and quality of SAE form completion and the real-time medical analysis by the Inserm Safety Department were major issues in the quick identification of potential safety signals. To conduct a high-quality clinical trial and ensure patient safety, all stakeholders must take their roles and responsibilities.

100 Deals associated with Interferon beta-1a biosimilar(Biocad Medical, Inc.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB07	DB00060

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	RU	Biocad Medical, Inc.	01 Jan 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	Phase 3	RU	Biocad CJSC	12 Feb 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02727907 (CTgov)	Phase 2/3	Multiple Sclerosis, Relapsing-Remitting	163	BCD-033 (interferon beta 1a) (BCD-033)	cbswlemeip(ggyrrkawff) = nwrjrjtjld pplkyvbacg (jiyrsqkqeu, zlusofxusa - azospidgzc) View more	-	17 Feb 2023
				Rebif (interferon beta 1a) (Rebif)	cbswlemeip(ggyrrkawff) = xaljuxkhvc pplkyvbacg (jiyrsqkqeu, wjndrgofmr - gorubzgnro) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Interferon beta-1a biosimilar(Biocad Medical, Inc.)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation